Takeda Pharmaceutical Company Limited (TAK)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
16.69-0.06 (-0.36%)
As of 12:10PM EST. Market open.
Show:
Annual
Income statement
Currency in JPY. All numbers in thousandsBreakdown
ttm
31/03/2020
31/03/2019
31/03/2018
31/03/2017
Total revenue
3,243,917,000
3,291,188,000
2,097,224,000
1,770,531,000
1,732,051,000
Cost of revenue
1,036,045,000
1,089,764,000
659,690,000
495,921,000
558,755,000
Gross profit
2,207,872,000
2,201,424,000
1,437,534,000
1,274,610,000
1,173,296,000
Operating expenses
Research development
482,336,000
492,381,000
368,298,000
325,441,000
312,303,000
Selling general and administrative
927,898,000
964,737,000
717,599,000
628,106,000
619,061,000
Total operating expenses
1,819,559,000
1,935,229,000
1,282,908,000
1,032,821,000
1,017,429,000
Operating income or loss
388,313,000
266,195,000
154,626,000
241,789,000
155,867,000
Interest expense
149,792,000
149,010,000
48,158,000
31,928,000
23,250,000
Total other income/expenses net
-192,403,000
-180,300,000
1,229,000
-32,199,000
-1,546,000
Income before tax
59,422,000
-60,754,000
94,896,000
217,205,000
143,346,000
Income tax expense
-60,354,000
-105,044,000
-14,118,000
30,497,000
27,833,000
Income from continuing operations
119,776,000
44,290,000
109,014,000
186,708,000
115,513,000
Net income
119,743,000
44,241,000
109,126,000
186,886,000
114,940,000
Net income available to common shareholders
119,743,000
44,241,000
109,126,000
186,886,000
114,940,000
Basic EPS
-
14.21
56.75
119.67
73.58
Diluted EPS
-
14.12
56.43
118.78
73.13
Basic average shares
-
3,132,408
1,922,954
1,561,613
1,562,215
Diluted average shares
-
3,132,408
1,933,794
1,573,379
1,571,722
EBITDA
-
671,905,000
415,500,000
431,260,000
389,383,000
© 2021 Verizon Media. All rights reserved.
